You are here

Zithromax EV in Community-Acquired Pneumonia (CAP)

Last updated on November 16, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects must require hospitalization and intravenous therapy.

- Subjects must have a Fine pneumonia score > 70 (Fine Class > II).

- Subjects must have a medical history and clinical and radiological findings
consistent with a community-acquired bronchopneumonia or lobar pneumonia. The
following criteria must be met:

- new infiltrate(s) on chest X-ray; AND

- at least two of the CAP signs or symptoms.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the
baseline visit, or treatment for more than 7 days within 15 days.

- Specific systemic diseases or other medical conditions that would interfere with the
evaluation of the therapeutic response or safety of the study drug, including:

- Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis
carinii pneumonia;

- Neutropenia;

- Cavitary lung disease by chest X-ray;

- Primary lung cancer or other malignancy metastatic to the lung;

- Aspiration pneumonia;

- Empyema;

- Known or suspected tuberculosis;

- Neoplastic disease;

- Cystic fibrosis;

- A history of any form of epilepsy or seizure;

- DDM;

- Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia
(this does not exclude patients with chronic obstructive pulmonary disease);

- Significant gastrointestinal or other conditions which may affect study drug
absorption; and

- Significant cardiovascular disorders.

- Immunosuppressive therapy, defined as chronic treatment with known immunosuppressant
medications

- Impaired hepatic function, as shown by, but not limited to, AST, (SGOT), or ALT
(SGPT) greater than three times the laboratory upper limit of normal, or total
bilirubin greater than two times the upper limit of normal.

- Subjects already hospitalized or who resided in a long-term-care facility for greater
than 14 days before the onset of symptoms.

NCT00137007
Pfizer
Completed
Zithromax EV in Community-Acquired Pneumonia (CAP)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
NCT04040621
All Genders
0+
Years
Multiple Sites
Descriptive Information
Brief Title  ICMJE Zithromax EV in Community-Acquired Pneumonia (CAP)
Official Title  ICMJE A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP)
Brief Summary

The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide.

This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy.

Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Pneumonia
Intervention  ICMJE
  • Drug: Azithromycin
  • Drug: Ampicillin/sulbactam
Study Arms  ICMJE Not Provided
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 20, 2011)
151
Original Enrollment  ICMJE
 (submitted: August 25, 2005)
150
Actual Study Completion Date  ICMJE September 2005
Primary Completion DateNot Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subjects must require hospitalization and intravenous therapy.
  • Subjects must have a Fine pneumonia score > 70 (Fine Class > II).
  • Subjects must have a medical history and clinical and radiological findings consistent with a community-acquired bronchopneumonia or lobar pneumonia. The following criteria must be met:

    • new infiltrate(s) on chest X-ray; AND
    • at least two of the CAP signs or symptoms.

Exclusion Criteria:

  • Treatment with any systemic antibiotic for 24 hours or longer within 72 hours of the baseline visit, or treatment for more than 7 days within 15 days.
  • Specific systemic diseases or other medical conditions that would interfere with the evaluation of the therapeutic response or safety of the study drug, including:

    • Known acquired immunodeficiency syndrome (AIDS) or suspected Pneumocystis carinii pneumonia;
    • Neutropenia;
    • Cavitary lung disease by chest X-ray;
    • Primary lung cancer or other malignancy metastatic to the lung;
    • Aspiration pneumonia;
    • Empyema;
    • Known or suspected tuberculosis;
    • Neoplastic disease;
    • Cystic fibrosis;
    • A history of any form of epilepsy or seizure;
    • DDM;
    • Bronchiectasis, bronchial obstruction or history of post-obstructive pneumonia (this does not exclude patients with chronic obstructive pulmonary disease);
    • Significant gastrointestinal or other conditions which may affect study drug absorption; and
    • Significant cardiovascular disorders.
  • Immunosuppressive therapy, defined as chronic treatment with known immunosuppressant medications
  • Impaired hepatic function, as shown by, but not limited to, AST, (SGOT), or ALT (SGPT) greater than three times the laboratory upper limit of normal, or total bilirubin greater than two times the upper limit of normal.
  • Subjects already hospitalized or who resided in a long-term-care facility for greater than 14 days before the onset of symptoms.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location CountriesItaly
 
Administrative Information
NCT Number  ICMJE NCT00137007
Other Study ID Numbers  ICMJE A0661082
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyNot Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateApril 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now